2 research outputs found
Efficacy of autologous platelet rich plasma for ovarian rejuvenation in infertile women having poor ovarian reserve
Background: Poor ovarian reserve (POR) is a condition in which the ovary loses its normal reproductive potential and compromising fertility. Normal function of the ovaries and adequate good quality follicles are responsible for the reproductive process of a woman. Various treatment methods exist for POR, but the present study was conducted to observe the effectiveness of platelet rich plasma infusion through measurement of AMH and AFC values and pregnancy outcomes.Methods: This prospective observational study was done in the department of reproductive endocrinology and infertility from July 2019 to June 2022. A total of 60 patients with poor ovarian reserve were recruited maintaining inclusion and exclusion criteria.Results: Mean age of the participants was 36.4 years, with 78.32% of the participants being housewives and 21.68% being service workers. 65.38% had education below SSC levels. 72.46% had primary infertility while 27.54% had secondary infertility. At first cycle, compared to baseline counts, mean±SD AMH had increased by 0.04±0.15 ng/dl, and mean±SD AFC had increased by 1.34±1.89 in number. During second cycle post-PRP, the mean difference of AMH and AFC was 0.18±0.21 ng/dl and 2.17±1.71 in a positive manner. By final follow-up, pregnancy rate was 20% among patients.Conclusions: The study observed significant improvement in AMH and AFC values following PRP infusion. The improvement of both values was gradual, and increase of AMH values were observed up to second post-PRP menstrual cycle, while AFC increased till third cycle post-PRP. Among 60 patient twelve (12) had pregnancy (20%)
Effects of autologous stem cell therapy for fertility enhancement among women with premature ovarian insufficiency
Background: Premature ovarian insufficiency (POI) is a condition where the ovary loses its normal reproductive potential earlier than 40 years, compromising fertility. There is no treatment for POI, only ovum or embryo donation. Autologous stem cell ovarian transplant (ASCOT) may be a procedure that creates new eggs in the ovaries of women with POI. The aim of the study was to find out the efficacy of ASCOT in patients suffering from POI.
Methods: A total of 50 patients were included according to inclusion and exclusion criteria in this prospective observational study. POI was confirmed with low levels of anti-mullerian hormone (AMH) (<0.5 ng/dl), high level of follicle stimulating hormone (FSH) >25 ng/ml, and or a low number of antral follicle count (AFC) (<3 in each ovary).
Results: Results showed that after stem cell therapy, mean AMH values increased by 0.48±0.306 and mean FSH values increased by 2.73±3.98 but the difference was not statistically significant. AFC values significantly decreased by 1.33±0.625 at 1st post-stem-cell cycle. During the second cycle, AMH and AFC increased by 0.110±0.051 and 4.63±1.49, respectively, and FSH decreased by 7.4±2.78. In third cycle, AMH & FSH was significantly increased by 0.820±0.44 & 4.120±0.470 and FSH has been decreased by 2.150±3.625. The increase in AMH & AFC was statistically significant, and the decrease in FSH was not statistically significant compared to baseline values.
Conclusions: The study showed that autologous stem cell therapy can have a significant effect on women’s ovarian function and fertility. It showed that ASCOT can increase AMH and AFC, and decrease FSH in patients with POI, with a total pregnancy rate of 4% after the third cycle follow-up